Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

3.5 hours. In seven out of 20 cases (35 percent), DP-PS correctly predicted the eventual outcome. These results seem to indicate that PS derived from DP model showed better correlation with drug exposure and could predict patient outcome better than Ktrans.

In a separate analysis, the effects of ABT-869 on biomarkers of angiogenesis were evaluated. Correlations of dose and pharmacokinetics of ABT-869, with serum biomarkers, tumor DCE-MRI tracer kinetics, proteinuria and hypertension were assessed. Results appeared to indicate that ABT-869 induced dose-dependent changes in serum biomarkers are consistent with anti-angiogenic activity. However, these serum biomarkers had limited value in predicting safety, i.e., proteinuria or hypertension. The utility of tumor flow and permeability changes on DCE-MRI in predicting proteinuria should be further examined. Updated information will be presented at the ASCO Annual Meeting.

Background on Abbott's Oncology Pipeline

Bcl-2 Family Protein Inhibitors (ABT-263)

Researchers have been interested in the Bcl-2 family of proteins since their role in preventing apoptosis -- the natural process by which damaged or unwanted cells die and are cleared from the body -- was proven more than a decade ago. Discovered by Abbott scientists, ABT-263 restores programmed cell death, a natural mechanism for the elimination of cancerous cells, by inhibiting the function of Bcl-2 proteins.

Bcl-2 proteins play a central role in regulating apoptosis, as well as tumor formation, tumor growth and resistance to treatment. Pioneering work in structural biology at Abbott established how the Bcl-2 family proteins interact with one another, leading researchers to develop a novel compound that causes cancer cells to self-destruct.

ABT-263 is in Phase I/II clinical trials for lymphomas and solid tumors, including small cell lung cancer. Preclinical data has shown that Abbott's Bcl-2 family protein inhibitors bind to Bc
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... a kind of disability. Researchers at Pope University, have found ... of aged people between 51 and 62.// ,Those ... cent more likely to report disabilities with respect to work ... greater risk. These were people who drank more than three ...
... aspirin because it thins the blood and prevents the ... widely used class of pain relievers known as nonsteroidal ... other aches and pains. The popular pain reliever ibuprofen ... study that sounds a warning for people who take ...
... are infected with HIV every year in the US, with ... of all U.S. patients with the AIDS virus have an ... to treat it. // Drug-resistant HIV had spread faster and ... normal lives were becoming increasingly limited in their usefulness. ...
... offer some protection against adult-onset diabetes.,An expert behind the ... benefit now by adding the spice to their food.// ... more prevalent than insulin-dependent diabetes, which normally begins earlier ... and insulin injections. It happens when cells in the ...
... is responsible for people who find it impossible to stay ... new treatments for jet lag//, insomnia and seasonal depression. ... cannot stay awake much after 8.30pm and who wake up ... advanced sleep-phase syndrome". This means the person's body clock is ...
... they have discovered the Holy Grail of bad smells ... effects of flatulence. American researchers believe the answer to ... that an object called a Toot Trapper, a cushion ... to almost unnoticeable levels. ,The scientists from ...
Cached Medicine News:Health News:Sniff out flatulence, 2
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 16 BioVex Inc, a biotechnology,company developing clinical ... that the abstract describing the interim results,from its ... advanced metastatic,melanoma is now available at the American ... http://www.asco.org . A summary of the abstract,which describes ...
... Nektar,s Technology Enables First-Ever PEGylation of a Small Molecule with ... Demonstrated Therapeutic ... NKTR ) announced initial results today from a Phase ... activity in patients with refractory solid tumors. The study,also demonstrates ...
Cached Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: